TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3189722
Drug: Diprospan (betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprospan (betamethasone dipropionate 5 mg and betamethasone disodium phosphate 2 mg per ml) injection
Study: 24815326
Drug: Aramchol 300
Normalized name: Aramchol
DrugBank: Aramchol (DB11860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aramchol 300 mg/day
Study: 20110638
Drug: Tumescent solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescent solution with a lidocaine concentration of 400 mg/l
Study: 20110638
Drug: Tumescent solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescent solution with a lidocaine concentration of 500 mg/l
Study: 10549449
Drug: Mefenamic acid,
Normalized name: Mefenamic Acid, 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefenamic acid, 500 mg twice a day for 5 days
Study: 8652318
Drug: Propofol sedation
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol sedation (initial i.v. boluses of 0.5 mg kg‐1 and fentanyl 1 microgram kg‐1, followed by an infusion of 50 micrograms kg‐1 min‐1)
Study: 8390014
Drug: Sequential immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential immunosuppression with ALG, azathioprine, and steroids for 14 days (group A)
Study: 8390014
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (14 days treatment)
Study: 8390014
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (2 days treatment)
Study: 28069072
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g × 4 and ibuprofen 400 mg × 4
Study: 28069072
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g × 4 and placebo
Study: 28069072
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and ibuprofen 400 mg × 4
Study: 28069072
Drug: Paracetamol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 0.5 g × 4 and ibuprofen 200 mg
Study: 21654268
Drug: Febuxostat 20
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 20 mg/d
Study: 16356696
Drug: Fluoxetine (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20-80 mg)
Study: 10932613
Drug: Cysplatin 60
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cysplatin 60 mg/m2 and Etoposide 120 mg/m2 (Group A)
Study: 8733686
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms G‐CSF/kg BW per day (group A)
Study: 20807343
Drug: Dexamethasone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 7.5 mg
Study: 26095339
Drug: Betamethasone 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone 6.0 mg
Study: 19215547
Drug: Intramuscular carbetocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular carbetocin (100 microg)
Study: 19215547
Drug: Intramuscular syntometrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular syntometrine (0.5 mg ergometrine and 5IU oxytocin)
Study: 8941027
Drug: Thioridazine 50
Normalized name: thioridazine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine 50 mg
Study: 12161768
Drug: Sildenafil (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25-100 mg)
Study: 7982251
Drug: Felodipine-ER (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-ER (5 mg once daily, increased to 10 mg if needed)
Study: 7982251
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30 mg once daily, increased to 60 or 90 mg if needed)
Study: 2972308
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (1 mg)
Study: 20216468
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (40 mg)
Study: 31065889
Drug: MoVo-LISA intervention
Normalized name: Movodyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: MoVo-LISA intervention (treatment as usual plus MoVo-LISA)
Study: 28483182
Drug: Acupressure (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure (two sessions, each lasting 20 minutes, administered one hour and three hours after attending the women's division)
Study: 21215550
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (PUFAs) 2 g
Study: 7551848
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment outcomes
Study: 8240450
Drug: Erythromycin acistrate
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin acistrate 800 mg daily
Study: 18720689
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg daily
Study: 3513767
Drug: Dazmegrel 50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dazmegrel 50-200 mg p.o.
Study: 3513767
Drug: Dazmegrel 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dazmegrel 100 mg b.i.d.
Study: 3513767
Drug: Dazmegrel 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dazmegrel 200 mg t.i.d.
Study: 3513767
Drug: Dazmegrel (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dazmegrel (all doses studied)
Study: 31882151
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (40 mg of dimethylprednisolone, injected once)
Study: 31882151
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma (PRP) injection (3 separate injections, 1 week apart)
Study: 28939343
Drug: Nurse-led home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led home-based exercise and cognitive behavioral therapy (E&CBT)
Study: 17270510
Drug: Robotic device
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic device exposure, 30 minutes a week, twice a week (exercises with unimpaired upper limb)
Study: 7844684
Drug: Chlorpromazine, 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine, 0.3 to 0.5 mg/kg intravenously every 4 to 6 hours, plus dexamethasone, 2 mg/m2 intravenously every 8 hours
Study: 30946703
Drug: Metamizole and
Normalized name: Metamizole
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizole and paracetamol
Study: 30946703
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and paracetamol
Study: 21790236
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg for 7 months
Study: 19366323
Drug: HPG containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPG containing ocular lubricant (Systane Lubricant Eye Drops; Alcon) administered four times daily (QID) for 28 days
Study: 9605675
Drug: Bolus dose
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose of propofol
Study: 9605675
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of propofol at rates of 25, 50, 100, or 200 microg x kg(‐1) x min(‐1)
Study: 3132571
Drug: Low-dose sustak-propranolol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sustak-propranolol combinations
Study: 23807155
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg TAF
Study: 8921778
Drug: r-hirudin (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hirudin (0.05 mg.kg‐1.h‐1)
Study: 8921778
Drug: heparin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin (target aPTT 65 to 90 seconds or 90 to 110 seconds)
Study: 30610099
Drug: Low‐to‐moderate PAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐to‐moderate PAE with discontinuation early in gestation
Study: 19788366
Drug: Present‐Centered Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present‐Centered Therapy
Study: 26882293
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure or Present‐Centered Therapy
Study: 10737133
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist (nicardipine hydrochloride retard tablet)
Study: 19438956
Drug: Bioceramic molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bioceramic molecular impregnated treatment (Ossean®)
Study: 11883552
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg B‐6
Study: 11883552
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg B‐6
Study: 7488415
Drug: CAV (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV (doxorubicin 50 mg/m2, vincristine 2 mg i.v. on day 1, cyclophosphamide 800 mg/m2 on day 1)
Study: 7488415
Drug: AVE (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVE (doxorubicin 50 mg/m2, vincristine 2 mg i.v. on day 1, etoposide 60 mg/m2 i.v. on day 1 and 120 mg/m2 orally on days 2-5)
Study: 2009895
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg b.d.
Study: 2009895
Drug: Nifedipine s.r.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine s.r. 20 mg b.d.
Study: 6616116
Drug: Pindolol (drug)
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol (drug)
Study: 29035597
Drug: CQA coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQA coffee (300 ml/day for 2 weeks)
Study: 24144876
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (oMP)
Study: 25145693
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (ivMP)
Study: 22304681
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone patch
Study: 19848045
Drug: Liraglutide (once-daily)
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide (once-daily)
Study: 19451556
Drug: Telmisartan, 80
Normalized name: Telmisartan, 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan, 80 mg/d (n = 2954)
Study: 15462099
Drug: Intravenous 1,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 1,25(OH)2D3 therapy (1-2 microg thrice a week for 12 weeks, mean dose 4.5 microg/week)
Study: 16420079
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (CT) alone
Study: 16420079
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) with fluvoxamine
Study: 6153164
Drug: Indirect fluorescent
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indirect fluorescent antibody technique (ethanol-fixed tissues)
Study: 6153164
Drug: Indirect fluorescent
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indirect fluorescent antibody technique (formalin-fixed tissues)
Study: 30760655
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard pharmacologic therapy)
Study: 24831394
Drug: Inhaled fenoterol/ipratropium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol/ipratropium
Study: 17479527
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) for 24 weeks
Study: 15611537
Drug: Patient Controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Controlled Analgesia (PCA) with morphine
Study: 7641721
Drug: Alfentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil infusion at the rate of 10 micrograms kg-1 h-1 (group III)
Study: 7641721
Drug: Alfentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil infusion at the rate of 20 micrograms kg-1 h-1 (group IV)
Study: 7641721
Drug: Alfentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil infusion at the rate of 40 micrograms kg-1 h-1 (group V)
Study: 7641721
Drug: Placebo bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bolus followed by placebo infusion (group I)
Study: 7641721
Drug: Alfentanil (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (any dosage) during abdominal surgery
Study: 2666710
Drug: Finoptin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finoptin (10 mg intravenous)
Study: 2666710
Drug: Phosphobion (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphobion (10 mg)
Study: 30716404
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg secukinumab
Study: 28493369
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg secukinumab
Study: 25092484
Drug: Type 2
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type 2 Diabetes PULSE Programme for Men (6-month, self-administered, gender-tailored lifestyle intervention)
Study: 19559374
Drug: Immediate postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate postoperative or salvage radiotherapy with androgen deprivation therapy
Study: 9486490
Drug: methylprednisolone or
Normalized name: methylprednisolone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone or methotrexate co-administration
Study: 26366058
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide LAR (60 mg every 28 days)
Study: 26366058
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR (40 mg every 28 days)
Study: 12107722
Drug: Mosapride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride (5 mg orally three times a day)
Study: 12107722
Drug: Mosapride (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride (8 weeks treatment)
Study: 2193172
Drug: Oral bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bacillus Calmette-Guerin (200 mg, 3 times each week)
Study: 2193172
Drug: Intravesical plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical plus percutaneous bacillus Calmette-Guerin (50 mg weekly for 6 weeks, then at 8, 10, and 12 weeks, then at 6 months and every 6 months thereafter)
Study: 31079155
Drug: Permanent polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permanent polymer drug-eluting stents (PP-DES)
Study: 30496408
Drug: Oral cholera
Normalized name: VIBRIO CHOLERAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholera vaccine (OCV)
Study: 24952227
Drug: Radiofrequency ablation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency ablation (RFA) therapy
Study: 19731119
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogen + 2.5 mg medroxyprogesterone (CEE/MPA) + one Cal+D tablet daily
Study: 19731119
Drug: one Cal+D
Approvals — FDA: no, EMA: no, PMDA: no
Description: one Cal+D tablet daily
Study: 18503924
Drug: Standard paper-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard paper-based insulin protocol
Study: 15922980
Drug: Mifepristone 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 5 mg daily for 1 year
Study: 15922980
Drug: Mifepristone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 10 mg daily for 1 year
Study: 8958387
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) prophylactic treatment for 2 weeks
Study: 8958387
Drug: PF4-heparin ELISA
Normalized name: Heparine
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PF4-heparin ELISA test
Study: 8958387
Drug: Daily platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily platelet count
Study: 3862040
Drug: 0.1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% chlorhexidine gluconate mouth rinse, twice daily
Study: 27312903
Drug: Dorzolamide-timolol fixed
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide-timolol fixed combination (DTFC)
Study: 15967511
Drug: Partial sleep
Normalized name: SOY OIL,PARTIALLY HYDROGENATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial sleep deprivation plus sertraline
Study: 19969374
Drug: Sertraline monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline monotherapy
Study: 10568861
Drug: Intraarticular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular morphine (3 mg)
Study: 11467238
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg)
Study: 11983043
Drug: Saline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (3 ml)
Study: 8908288
Drug: OK-432 (immunotherapy)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 (immunotherapy)
Study: 27442314
Drug: Omega-3 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 group (4 softgels containing 1680 mg eicosapentaenoic acid/560 mg docosahexaenoic acid daily for 12 weeks)
Study: 27442314
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3136 mg of linoleic acid daily for 12 weeks)
Study: 23548420
Drug: Intramyocardial Multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial Multiple Precision Administration of Mononuclear Bone Marrow Cells (MBMC)
Study: 21926634
Drug: Once-daily efavirenz
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily efavirenz doses of 200, 250, 300, 350 mg based on weight bands
Study: 21926634
Drug: Once-daily efavirenz
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily efavirenz doses
Study: 14729722
Drug: Opioid-receptor antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Opioid-receptor antagonist (16 mg naloxone)
Study: 14729722
Drug: Opioid-receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-receptor agonist (60 mg codeine)
Study: 7686065
Drug: Transurethral microwave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral microwave treatment
Study: 2826749
Drug: Dentifrice consisting
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dentifrice consisting of sodium bicarbonate and 3% hydrogen peroxide or 3% hydrogen peroxide alone with 5 M NaCl irrigating solution
Study: 24171260
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g P. tuberosa in two divided doses
Study: 19369186
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups allowed to take 200 mg celecoxib per day
Study: 19369186
Drug: Global assessment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Global assessment of change after 10 treatments
Study: 12468605
Drug: Lutein diester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein diester formulation (0.67 micro mol lutein/kg body)
Study: 12468605
Drug: Unesterified lutein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unesterified lutein formulation (0.5 micro mol lutein/kg body)
Study: 12468605
Drug: Oil-solubilized unesterified
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil-solubilized unesterified lutein preparation (0.5 micro mol/kg body)
Study: 9469323
Drug: Luteinizing hormone-releasing
Normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone-releasing hormone (LHRH) agonist plus placebo (LHRH+P group)
Study: 7848897
Drug: NTG patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG patches delivering low (15-30 mg/24 hr)
Study: 7848897
Drug: NTG patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG patches delivering moderate (45-60 mg/24 hr)
Study: 22518377
Drug: 6 mm-long,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mm-long, 4 mm-wide implants
Study: 22518377
Drug: at least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: at least 10 mm-long implants in augmented bone
Study: 17509302
Drug: 25 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m2 vinorelbine (arm B)
Study: 12375715
Drug: Suplatast tosilate
Normalized name: Edoxaban Tosylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suplatast tosilate (100 mg t.i.d. for 28 days)
Study: 10980831
Drug: Intervention with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention with agents that lower triglycerides and raise HDL
Study: 2185042
Drug: Timed intercourse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed intercourse with clomiphene citrate (CC)
Study: 74317
Drug: Alcohol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol plus pyrithioxine (7 mg/kg)
Study: 30234616
Drug: Clostridium butyricum
Normalized name: Clostridium butyricum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clostridium butyricum MIYAIRI 588 (CBM588) 60 mg/d in combination with antidepressants
Study: 17294999
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide
Study: 18158814
Drug: 40 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mcg/kg granisetron
Study: 18158814
Drug: 15 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mcg/kg ondansetron
Study: 25040766
Drug: 0.25% sodium
Normalized name: Supred, 0.25% sodium phosphate-10% ophthalmic suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% sodium hypochlorite oral rinse
Study: 17964576
Drug: Antimuscarinic drug
Normalized name: ANTIMUSCARINICS/ANTISPASMODICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimuscarinic drug scopolamine (SCOP)